Chart-Typ:
Zeitraum:
| Oruka Therapeutics, Inc.: Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September | IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026 Interim Phase 1 data and further details on EVERLAST-A study design to... ► Artikel lesen |
| Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer | MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard... ► Artikel lesen |
| Oruka Therapeutics, Inc.: Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody | Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two... ► Artikel lesen |
| Palvella Therapeutics Inc.: Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% | Enrollment of 51 subjects highlights significant unmet need in this serious, lifelong genetic disease which currently has no FDA-approved therapies Top-line data expected in the first quarter of 2026... ► Artikel lesen |
| Palvella Therapeutics Inc.: Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors | New intellectual property builds on Palvella's multi-layered exclusivity strategy Patent term expected through at least 2038 WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics... ► Artikel lesen |
| Palvella Therapeutics Inc.: Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations | FDA Orphan Products Grants are awarded based on rigorous scientific and technical review by rare disease and regulatory experts Up to $2.6 million in non-dilutive funding anticipated over the grant... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PARDES BIOSCIENCES INC finden Sie auf Wallstreet Online.